New drug shows promise for back pain from ankylosing spondylitis
NCT ID NCT07498634
First seen Apr 04, 2026 · Last updated May 02, 2026 · Updated 6 times
Summary
This study tested a new antibody drug (XKH004) in 323 adults with moderate-to-severe active ankylosing spondylitis, a type of arthritis that causes back pain and stiffness. The drug aims to reduce inflammation by blocking certain proteins. Participants received either the drug or a placebo, and the main goal was to see if more people on the drug had a 40% improvement in symptoms after 16 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHASE III are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Changzheng Hospital
Shanghai, China
Conditions
Explore the condition pages connected to this study.